Moreover, augmented mineralocorticoid activity is increasingly documented in patients with resistant hypertension and so-called low-renin hypertension, considering the efficiency of mineralocorticoid receptor (MR) blockade in these patients (Ferrario and Schiffrin, 2015). This evidence concerns the gene REN and hypertensive disorder.